Teodora-Adriana Perles-Barbacaru1, Feriel Tiar2, Laurent Pelletier2, Didier Wion2, Francois Berger2, Hana Lahrech1
1INSERM U836, Functional & Metabolic Neuroimaging, Grenoble Institute of Neurosciences, University Joseph Fourier, Grenoble, France; 2INSERM U836, Brain Nanomedicine Group, Grenoble Institute of Neurosciences, University Joseph Fourier, Grenoble, France
To assess angiogenesis in a novel orthotopic mouse model derived from human glioblastoma stem cells, quantitative blood volume fraction (BVf) mapping was performed using dynamic Rapid Steady State T1 MRI with the clinically approved low molecular weight contrast agent Gd-DOTA. While the tumor occurrence was hardly detectable with T2-weighted imaging during the 2nd month of tumor development, the tumor BVf was increased (0.034 0.010) compared to the contralateral cerebral BVf (0.023 0.004) without increased vascular permeability to Gd-DOTA. This slowly growing tumor model can be useful for the preclinical evaluation of antiangiogenic therapies.